Cosyntropin vs L-692,429
Head-to-head comparison of Cosyntropin (Cosyntropin (ACTH 1-24)) and L-692,429 (L-692,429) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Cosyntropin | L-692,429 |
|---|---|---|
| Category | Pain Management | Growth Hormone |
| Full Name | Cosyntropin (ACTH 1-24) | L-692,429 |
| Molecular Weight | 2933.3 Da | N/A |
| Half-Life | ~10 min | unknown / study-dependent |
| Amino Acids | 24 | N/A |
| Typical Dose | 0.25 mg IV/IM diagnostic dose|off-label headache protocols vary | 0.03-0.1 mg/kg |
| Route | IV|IM | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 61 | 30 |
| Research Status | Clinical research | Pre-clinical |
Cosyntropin Benefits
- ✓refractory migraine
- ✓anti-inflammatory signaling
- ✓headache rescue research
L-692,429 Benefits
- ✓potent GHSR agonism
- ✓oral bioactivity in models
- ✓validates ghrelin pathway
- ✓useful research probe
Cosyntropin Dosing
0.25 mg IV/IM|1 mg IV/IM
L-692,429 Dosing
0.03-0.1 mg/kg in early studies|single oral or short-course research dosing|serial GH sampling recommended
Cosyntropin Side Effects
- ⚠flushing
- ⚠nausea
L-692,429 Side Effects
- ⚠increased appetite
- ⚠glucose intolerance
- ⚠transient prolactin changes
Research Overview
Cosyntropin
Cosyntropin is not a standard pain drug, but it appears in headache literature because ACTH analogs can help some patients with difficult migraine attacks. The analgesic rationale is partly tied to steroidogenic and anti-inflammatory effects.
L-692,429
L-692,429 was important in early GH secretagogue research because it showed that nonpeptide molecules could trigger robust GH release. It remains a classic tool compound for studying receptor-mediated GH pulsatility and appetite signaling.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.